Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Lxo Ireland Designated Activity Company
Sars-CoV2
1 trial -
ALN-6400
Alnylam Netherlands B.V.
Hereditary Hemorrhagic Telangiectasia
1 trial -
APR-246
Aprea Therapeutics
Melanoma
1 trial -
APX005M
Pyxis Oncology
Melanoma
1 trial -
ARC-520
Arrowhead Pharmaceuticals Ireland Limited
Hepatitis B
2 trials -
ARC-520
Arrowhead Pharmaceuticals Ireland Limited
Chronic Hepatitis B
1 trial -
ARC-520
Arrowhead Pharmaceuticals Ireland Limited
Hepatitis B, Chronic
1 trial -
ARC-520 Injection
Arrowhead Pharmaceuticals Ireland Limited
Hepatitis B
2 trials -
ARC-520 Injection
Arrowhead Pharmaceuticals Ireland Limited
Chronic Hepatitis B
1 trial -
ARC-AAT Injection
Arrowhead Pharmaceuticals Ireland Limited
Alpha-1 Antitrypsin Deficiency
2 trials -
ARO-AAT
Arrowhead Pharmaceuticals Ireland Limited
Alpha 1-Antitrypsin Deficiency
1 trial -
ARO-ALK7
Arrowhead Pharmaceuticals Ireland Limited
Obesity
1 trial -
ARO-ANG 3 Injection
Arrowhead Pharmaceuticals Ireland Limited
Homozygous Familial Hypercholesterolemia
1 trial -
ARO-ANG3
Arrowhead Pharmaceuticals Ireland Limited
Mixed Dyslipidemia
1 trial -
ARO-APOC3
Arrowhead Pharmaceuticals Ireland Limited
Mixed Dyslipidemia
1 trial -
ARO-APOC3
Arrowhead Pharmaceuticals Ireland Limited
Mixed Dyslipidemia
1 trial -
ARO-APOC3
Arrowhead Pharmaceuticals Ireland Limited
Dyslipidemias
1 trial -
ARO-APOC3
Arrowhead Pharmaceuticals Ireland Limited
Severe Hypertriglyceridemia
1 trial -
ARO-C3
Arrowhead Pharmaceuticals Ireland Limited
complement-mediated renal disease
1 trial -
ARO-C3
Arrowhead Pharmaceuticals Ireland Limited
C3 Glomerulopathy
1 trial -
ARO-DIMERPA
Arrowhead Pharmaceuticals Ireland Limited
Hyperlipidemia; Mixed
1 trial -
ARO-DM1 Intravenous (IV) Infusion
Arrowhead Pharmaceuticals Ireland Limited
Myotonic Dystrophy 1
1 trial -
ARO-DUX4 for Injection
Arrowhead Pharmaceuticals Ireland Limited
Facio-Scapulo-Humeral Dystrophy
1 trial -
ARO-ENaC
Arrowhead Pharmaceuticals Ireland Limited
Cystic Fibrosis, Pulmonary
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources